Genoox Overview
Genoox is a healthcare and technology company aiming to make clinical genetic sequencing more accessible. Using the companys cloud-based advanced framework encompassing purpose-built applications, users can easily manage the entire genetic sequencing process and create virtual genetic test modules providing plug-and-play options for the delivery of clinical actionable insights and disease diagnoses. Driven by artificial intelligence technology, the companys product, Franklin, integrates data from published literature and publicly available population, disease, and sequence databases and employs machine learning to derive a prediction aggregation score and adjust the weights of ACMG classification criteria. Genoox removes the final barrier to widespread adoption of clinical NGS, enabling personalized medicine for mainstream patients. Its platform is used in the diagnosis and treatment of genetic disorders and cancer, as well as new drug discovery and family planning. Genoox aims to improve patient outcomes with increased accuracy and efficiency, enabling personalized medicine and patient-specific treatments.
Cumulative Funding Raised Over Time ($)
—Apr 2024
—Aug 2014
$6.0MJul 2017
$6.0MMar 2016
$12.0MMay 2018
$20.0MMay 2021
Latest News
growth-positive
ג'ינוקס, המפתחת מערכת לניתוח מידע גנטי, נמכרת לחברת קיאג'ן ההולנדית בעסקה הכוללת תשלום של 70 מיליון דולר במזומן, ועוד 10 מיליון דולר המותנים בהשגת אבני דרך ■ מאז הקמתה ב-2014 גייסה ג'ינוקס 26 מיליון דולר
Genoox, an Israeli biomed company specializing in genetic data analysis systems, has been acquired by the Dutch diagnostics company QIAGEN. The acquisition deal is valued at up to $80 million, with an initial payment of $70 million in cash and an additional $10 million contingent upon achieving future milestones. Since its founding in 2014, Genoox has raised $26 million. This acquisition marks a significant growth opportunity for Genoox, allowing it to leverage QIAGENs resources and market reach. The transaction highlights the ongoing consolidation in the biomed sector, particularly in the field of genetic analysis.
Acquired-by
Genoox partners with Thermo Fisher Scientific to automate cytogenetic research data interpretation and reporting with AI
https://www.bakersfield.com/ap/news/element-biosciences-partners-with-interpretation-expert-genoox-to-validate-the-aviti-system-for-the-rugd/article_bab109f0-b7cd-5fa3-85cf-19216003dc33.html
growth-positive
Genoox Names Andy Page to lead its Advisory Board
Genoox, a community-driven genomic data platform, has announced that Andy Page has joined as the leader of its Advisory Board. Pages extensive knowledge and experience in the healthcare industry will help the company scale up quickly. Genooxs platform connects clinicians, genetic counselors, and healthcare organizations, providing a comprehensive analysis of genomic data supported by AI and ML tools. With Pages leadership, the company aims to disrupt the healthcare industry by making curated real-world data instantly accessible and accelerating time to answers for professionals. Genoox has experienced significant growth, with its community of genetic users growing four times over the past year. The company plans to further scale up in 2022 and beyond.
Management Changes
growth-positive
Genoox accelerates genomic data community platform expansion with $8M round and appointment of new Board Chair
Genoox, a community-driven genomic data platform, has raised $8 million in a funding round led by IN Venture. The investment will allow the company to expand its community of genetic professional users and enhance the network effect on its platform. Additionally, Ohad Arazi has been appointed as Chairman of the Board. Genoox aims to leverage genomic data to drive the precision medicine revolution and make new clinical discoveries. The companys community of users is rapidly growing and generating valuable insights in various domains. The partnership with Sumitomo Corporation and the addition of Ohad Arazi are expected to further accelerate Genooxs growth and commercialization efforts.
InvestmentManagement Changes
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $20M |
| Last funding | Undisclosed |
| Stage | Acquired |
| Rounds | 6 |
| Investors | 9 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | www.genoox.com/ |
| Careers | Careers page |
Locations
Tel Aviv-Yafo, Israel
550 California Avenue, Palo Alto, CA, USA
New York City, NY, USA
Photos & Videos
1 item(s)
Genoox Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportTarget Customer
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticalsCore Technology
Artificial IntelligenceMachine LearningData StorageCloudPlatforms & InterfacesSoftwareTags (24)
clinical-trialsdoctorsbig-datagenomicsdigital-healthcaredata-managementdiagnosticsartificial-intelligenceprecision-medicinedata-analyticsdeep-learningcloud-basedpersonalizationhealthcare-providerssoftware-platformcanceractionable-insightspharma-companiesgenetic-disordersmachine-learningdrug-discoveryclinicsdecision-supportbioconvergenceGeographic Markets
South AmericaUnited StatesAustraliaIndiaEuropeAsiaGenoox Financials
$20M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Acquired
Funding stage
6
Total rounds
9
Investors
Cumulative Funding Raised Over Time ($)
—Apr 2024
—Aug 2014
$6.0MJul 2017
$6.0MMar 2016
$12.0MMay 2018
$20.0MMay 2021
Private Equity Funding
Undisclosed Round
Apr 2024
Undisclosed
Artofin
B Round
May 2021
$8M
IN Venture (Lead)
,
Inimiti, Glilot Capital Partners, Infinity Medical, Triventures
B Round
May 2018
$6M
Glilot Capital Partners, Initial Capital
A Round
Jul 2017
$6M
Glilot Capital Partners, Inimiti
Undisclosed Round
Mar 2016
Undisclosed
Microsoft Accelerator Tel Aviv
Seed
Aug 2014
Undisclosed
UpWest
Public Offering / Exit
MNAEvent
May 2025
$80M
Genoox Lifecycle
Cumulative Funding Raised Over Time
—Apr 2024
—Aug 2014
$6.0MJul 2017
$6.0MMar 2016
$12.0MMay 2018
$20.0MMay 2021
All Events
Undisclosed Round
Apr 2024
Undisclosed
Artofin
B Round
May 2021
$8M
IN Venture (Lead)
,
Inimiti, Glilot Capital Partners, Infinity Medical, Triventures
B Round
May 2018
$6M
Glilot Capital Partners, Initial Capital
A Round
Jul 2017
$6M
Glilot Capital Partners, Inimiti
Undisclosed Round
Mar 2016
Undisclosed
Microsoft Accelerator Tel Aviv
Seed
Aug 2014
Undisclosed
UpWest
MNAEvent
May 2025
$80M
Genoox News
15 articles
growth-positive
ג'ינוקס, המפתחת מערכת לניתוח מידע גנטי, נמכרת לחברת קיאג'ן ההולנדית בעסקה הכוללת תשלום של 70 מיליון דולר במזומן, ועוד 10 מיליון דולר המותנים בהשגת אבני דרך ■ מאז הקמתה ב-2014 גייסה ג'ינוקס 26 מיליון דולר
Genoox, an Israeli biomed company specializing in genetic data analysis systems, has been acquired by the Dutch diagnostics company QIAGEN. The acquisition deal is valued at up to $80 million, with an initial payment of $70 million in cash and an additional $10 million contingent upon achieving future milestones. Since its founding in 2014, Genoox has raised $26 million. This acquisition marks a significant growth opportunity for Genoox, allowing it to leverage QIAGENs resources and market reach. The transaction highlights the ongoing consolidation in the biomed sector, particularly in the field of genetic analysis.
Acquired-by
Genoox partners with Thermo Fisher Scientific to automate cytogenetic research data interpretation and reporting with AI
https://www.bakersfield.com/ap/news/element-biosciences-partners-with-interpretation-expert-genoox-to-validate-the-aviti-system-for-the-rugd/article_bab109f0-b7cd-5fa3-85cf-19216003dc33.html
growth-positive
Genoox Names Andy Page to lead its Advisory Board
Genoox, a community-driven genomic data platform, has announced that Andy Page has joined as the leader of its Advisory Board. Pages extensive knowledge and experience in the healthcare industry will help the company scale up quickly. Genooxs platform connects clinicians, genetic counselors, and healthcare organizations, providing a comprehensive analysis of genomic data supported by AI and ML tools. With Pages leadership, the company aims to disrupt the healthcare industry by making curated real-world data instantly accessible and accelerating time to answers for professionals. Genoox has experienced significant growth, with its community of genetic users growing four times over the past year. The company plans to further scale up in 2022 and beyond.
Management Changes
growth-positive
Genoox accelerates genomic data community platform expansion with $8M round and appointment of new Board Chair
Genoox, a community-driven genomic data platform, has raised $8 million in a funding round led by IN Venture. The investment will allow the company to expand its community of genetic professional users and enhance the network effect on its platform. Additionally, Ohad Arazi has been appointed as Chairman of the Board. Genoox aims to leverage genomic data to drive the precision medicine revolution and make new clinical discoveries. The companys community of users is rapidly growing and generating valuable insights in various domains. The partnership with Sumitomo Corporation and the addition of Ohad Arazi are expected to further accelerate Genooxs growth and commercialization efforts.
InvestmentManagement Changes
growth-positive
הסטארט-אפ שמסייע להתאים את הטיפול למבנה הגנטי האישי -
Israeli start-up Genoox, founded by Amir Trabelsi and Moshe Einhorn in 2014, has developed a system for analyzing DNA to help doctors, clinicians, and researchers implement genetic sequencing results in various medical applications. The company, which raised $6 million in 2018 to expand its team, is working in partnership with the Ministry of Health as part of a national digital health project to monitor and sequence the genome of 100,000 Israeli citizens. Genooxs platform simplifies the management and interpretation of genetic data combined with clinical and historical data on the patient, leading to wider adoption of genomic information in patient care decisions.
InvestmentPartnersExpand
growth-positive
Bionano Genomics to Support Largest Study to Date on COVID-19 Disease Susceptibility
Bionano Genomics has launched a study to identify genomic variants and novel active substances that influence resistance or sensitivity to the SARS-CoV2 virus. The study involves 1,000 patients and controls and aims to identify genomic variants that affect the disease and immune or metabolic variables that can protect against more severe disease. Bionano Genomics is donating consumables, Rescale and Amazon Web Services are donating compute resources, and Genoox is donating their compute resources for the analysis of genomic variants. The study is part of the global Tech Against Covid initiative. The results will be shared with the medical and research community.
PartnersInvestment
growth-positive
Genoox Launches Genetic Data Reanalysis Capabilities to Solve for Disconnect Between Clinical Evidence and Application
Genoox, a healthcare technology company, has announced major updates to its platform. The updates use artificial intelligence-based tools to promote regular genomic data reanalysis and data aggregation, improving diagnoses for patients based on new clinical evidence. The platform can automatically alert customers when genetic samples contain previously unidentified mutations. This eliminates the need for labs to constantly run manual tests. Genoox aims to bridge the technology disconnect between academic literature and real-world applications of NGS. The companys platform is expected to benefit sick patients with unidentified conditions, families seeking answers, and future patients with the same mutations. The collaboration between Genoox and Scripps Research holds promise for advancing science and medicine.
CustomersPartners
growth-positive
Bionano and Genoox Launch Integrated Platform for Identification of Structural Variants in DNA
Bionano Genomics and Genoox have announced the launch of the Genoox Integrated Platform for the identification of structural variants. The platform combines Bionanos Saphyr system and Genoox technology to provide sensitive and accurate detection of structural variation and genetic mutations. The platform will help speed up genetic diagnosis by combining raw NGS read data with Bionano-based SV calls from a single patient. The companies will begin to co-sell and co-market the integrated platform immediately.
PartnersExpand
growth-positive
Genoox and Microsoft Healthcare partner to help advance precision medicine
Genoox has announced a partnership with Microsoft Healthcare to bring Microsoft Genomics service to its global customers. This partnership aims to advance precision medicine by combining Genooxs genetic data translation capabilities with Microsofts Azure cloud and AI technologies. Genoox provides a SaaS platform for developing NGS-based genetic applications, and by integrating Microsoft Genomics pipeline, it will enable rapid analysis and actionable insights for clinicians and researchers. The collaboration is expected to improve patient outcomes and reduce time to market for clinical applications.
Partners
growth-positive
Israeli genomic analysis co Genoox raises $6m
Israeli genomic analysis company Genoox has closed a $6 million financing round led by Triventures. The startup aims to make it easier for doctors, clinicians, and researchers to analyze and act on genetic sequencing results. Genoox employs machine learning algorithms to analyze large amounts of genetic data and is transforming the market by offering broader tests that cover large parts of the genome. The company has partnerships with medical centers and research facilities and has recently partnered with Bionano Genomics to enhance the detection of disease-causing structural variants in DNA.
InvestmentPartners
Genoox Collaborates with Bionano to Enhance the Detection of Disease Causing Structural Variants in DNA
Growth-Positive
The Importance Of Data Governance In The Future Of Healthcare
Genoox, a data analytics start-up, has partnered with the 100,000 Israeli Genome Project to analyse genetic data and provide actionable insights to hospitals, clinical labs and researchers throughout Israel. The partnership is part of Genooxs expansion, which was supported by a recent $6m funding round. The company aims to make genetic sequencing more accessible. The article also discusses the importance of robust data governance in healthcare, as the industry becomes more data intensive. It highlights the need for clear legal and ethical principles around consent, especially as more genomic data is generated.
CustomersPartnersInvestmentExpand
growth-positive
Genoox Betting On Variant Classification Tech to Bring More NGS to Community Hospitals
Genomic analysis startup Genoox has entered the US market and raised $6 million in a Series A round of private equity investment. The company has developed an AI engine to classify genetic variants based on medical guidelines, with the aim of making next-generation sequencing more accessible to community hospitals and laboratories. Genooxs technology can lower sequencing costs by up to 90% and reduce turnaround time to minutes. The company plans to be an end-to-end supplier, providing data analytics services to integrate genomic sequencing information into clinical workflows. The target market is community hospitals and independent labs, and Genoox aims to address the bottleneck of clinical reporting. The company also plans to expand its platform to analyze germline mutations and focus on rare diseases, childhood disorders, hereditary diseases, and cancers.
InvestmentExpand
growth-positive
Genoox raises $6M to make genetic data analysis more accessible for clinics
Genoox, a startup that facilitates the use of genomic data in patient care, has raised $6 million in funding. The funding will be used for the companys expansion into the U.S. Genooxs software is already used by top genetic medicine institutes and labs in Israel, and it was contracted by the Israeli government for a genomic data analysis project. The companys technology uses machine-learning algorithms to analyze rare genetic mutations and predict their probability of causing a condition. Genoox aims to make genetic sequencing more accessible and less time-consuming for clinics. The companys platform can examine data from both whole-genome sequencing and whole-exome sequencing, and it plans to create new applications for genetic testing.
InvestmentExpand
Genoox Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 58 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 14 classification IDs that could be used for matching.
Genoox Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Crunchbase | genoox |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-09-09T00:00:00.000Z |
| Created | 2014-07-29T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Acquired by Qiagen on May, 2025 |